|Other Names||Osteocalcin, Bone Gla protein, BGP, Gamma-carboxyglutamic acid-containing protein, BGLAP|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2002a was selected from the N-term region of human osteocalcin . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Prior to the formation of calcified bone, noncollagenous proteins form in the extracellular bone matrix. Gamma-carboxyglutamic acid residues are formed by vitamin K, vitamin-D regulated calcium binding proteins containing residues of Gla. These residues are essential for the binding of calcium and constitue 1-2% of total bone protein. Osteocalcin itself binds strongly to apatite and calcium. Production of osteocalcin is expressed late in normal bone development and is characteristic of mature osteoblasts. Regular osteocalcin production has been shown to be linked to the p53 tumor suppressor gene. The p53 gene undergoes rearrangement in a high percentage of osteosarcomas, resulting in loss of its expression. The loss of p53 regulation inhibits further osteocalcin production. The absence of end-point differentiation in bone due to p53 rearrangements and lack of osteocalcin production may contribute to the maintenance of the tumorigenic phenotype in osteosarcomas.
Yamada, Y., et al., J. Clin. Endocrinol. Metab. 88(7):3372-3378 (2003).Gronthos, S., et al., J. Bone Miner. Res. 18(4):716-722 (2003).Yousfi, M., et al., Biochem. Biophys. Res. Commun. 297(3):641-644 (2002).Willis, D.M., et al., J. Biol. Chem. 277(40):37280-37291 (2002).Viereck, V., et al., J. Cell. Biochem. 86(2):348-356 (2002).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.